POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
High Impact

Missouri bill exempts veterans and first responders from penalties for therapeutic psilocybin use under specific clinical studies

Original title: Modifies provisions relating to alternative therapies and treatments, including psilocybin

Last action · May 7, 2026: Second Read and Referred S Emerging Issues and Professional Registration CommitteeSponsor: Rick Brattin

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Would Do

Under Senate Bill 1767, eligible veterans and first responders aged 21 or older diagnosed with specific conditions like PTSD or major depressive disorder are exempt from state and local civil or criminal penalties for therapeutic psilocybin use when enrolled in an approved study. The legislation caps individual use at 150 milligrams of per year, requires a qualified to be present during administration, and appropriates $2 million for efficacy research through the Department of Mental Health.

Why it matters

Qualifying veterans and first responders gain legal immunity to use psilocybin for specific mental health conditions and end-of-life care without facing criminal prosecution or professional licensure discipline, while participating physicians and assisting individuals are similarly shielded from state liability.

Background
  • Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, currently classified as a Schedule I controlled substance under federal law. context
  • State legislation concerning alternative therapies for veterans often seeks to address high rates of posttraumatic stress disorder and treatment-resistant depression. context

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Veterans and First Responders

Individuals meeting age and health criteria gain legal immunity from civil and criminal penalties when using therapeutic psilocybin within study and dosage limits.

Directly affected

Physicians and Health Care Providers

Medical professionals providing documentation, referrals, or care related to approved therapies are protected from criminal liability and professional license discipline.

Directly affected

Department of Mental Health

The department is tasked with collecting participant data, maintaining confidentiality, distributing research grants, and reporting annually to state leadership.

Directly affected

State-licensed Laboratories

Laboratories testing controlled substances or cannabis are granted immunity from criminal or civil penalties when testing psilocybin for authorized program participants.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Who is eligible to use therapeutic psilocybin without facing penalties under SB 1767?
Veterans and first responders who are 21 years of age or older, suffer from posttraumatic stress disorder, major depressive disorder, a substance use disorder, or require end-of-life care, and are enrolled in a qualifying study are eligible.
Are there limits on how much psilocybin a person can use?
Yes, a participant must limit the use of psilocybin to no more than 150 milligrams of during any 12-month period.
Who must be present when a person uses psilocybin under this bill?
The use of psilocybin must occur only in the presence of a qualified , such as a licensed physician, licensed mental health professional, or other specified licensed clinical practitioner who has completed specialized psilocybin training.
Can state agencies share a participant's personal information with the federal government?
No. State agencies and employees are strictly prohibited from disclosing statewide participant lists or individual information to the federal government or any unauthorized third party.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

2 actions
  1. May 7, 2026SenateFloor
    Second Read and Referred S Emerging Issues and Professional Registration Committee
  2. Feb 26, 2026SenateIntroduced
    S First Read

Version history

Only one version on file - nothing to compare yet. The text on record is the 7497S.01I - Introduced version. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift98% confidence

State-Level Criminal Penalty Exemption for Therapeutic Psilocybin

The bill creates a conditional legal carve-out from state and local criminal penalties for qualifying veterans and first responders utilizing psilocybin under clinical study frameworks.

Connected Entities

Department of Mental Health, Department of Corrections, Department of Veterans Affairs and 8 more
OrganizationDepartment of Mental Health“State agency tasked with receiving participant information, administering resear”Map →
OrganizationDepartment of Corrections“Not required to provide coverage for investigational drugs or devices”Map →
OrganizationDepartment of Veterans Affairs“Federal agency defining veteran status”Map →
OrganizationAmerican Psychedelic Practitioners Association“Professional association whose guidelines inform facilitator training standards”Map →
OrganizationGeneral Assembly“State legislative body receiving annual departmental implementation reports”Map →
PersonRick Brattin“Senator representing District 31 who introduced SB 1767”Map →
OrganizationAmerican Psychological Association“Professional association whose psychedelic-assisted therapy guidelines inform fa”Map →
OrganizationUnited States Food and Drug Administration“Federal agency regulating drug approvals and clinical trials”Map →
PersonKristina Martin“Secretary of the Senate”Map →
PersonGovernor“Recipient of Department of Mental health annual implementation and study reports”Map →
PersonLieutenant Governor“Recipient of Department of Mental Health annual reports”Map →

Sources

Open source document

www.senate.mo.gov

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy80
    Intensity of disagreement among stakeholders
  • Entertainment15
    Compellingness for a non-policy-wonk reader
  • Buzz70
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record